Literature DB >> 18782327

Generation of functionally mature dendritic cells from elutriated monocytes using polyinosinic : polycytidylic acid and soluble CD40 ligand for clinical application.

S Kim1, H O Kim, H J Kim, K Lee, H-S Kim.   

Abstract

Despite the increasing use of dendritic cell (DC) vaccination in clinical trials, optimal conditions for the generation of functionally mature DCs remain to be established. The current standard DC maturation protocol for clinical trials has been used as an inflammatory cytokine cocktail [tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6 and prostaglandin E(2)], but this cocktail induced insufficient maturation of DCs derived from elutriated monocytes when cultured in X-VIVO 15. The aim of this study was to define effective combinations of stimulators for generating functionally mature DCs from elutriated monocytes under current good manufacturing practice conditions. We compared the functional capacity of DCs in response to all possible pairwise combinations of four different classes of stimuli: TNF-alpha, peptidoglycan, polyinosinic : polycytidylic acid [poly(I:C)] and soluble CD40 ligand (CD40L). Maturation status of DCs stimulated with combination of four stimuli was similar to that of the cytokine cocktail as assessed by the cell surface phenotype. However, only the combination of poly(I:C) + CD40L induced complete functional activation of the whole DC population, assessing IL-12p70 production, allostimulatory activity, migratory response to CCL19 and T helper 1-polarizing capacity. Thus, the protocol based on the combination of poly(I:C) and CD40L is more effective for the induction of clinical-grade DCs from elutriated monocytes than the standard cytokine cocktail.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18782327      PMCID: PMC2633224          DOI: 10.1111/j.1365-2249.2008.03757.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  41 in total

1.  The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells.

Authors:  G De Becker; V Moulin; B Pajak; C Bruck; M Francotte; C Thiriart; J Urbain; M Moser
Journal:  Int Immunol       Date:  2000-06       Impact factor: 4.823

2.  Monocyte-derived CD1a+ and CD1a- dendritic cell subsets differ in their cytokine production profiles, susceptibilities to transfection, and capacities to direct Th cell differentiation.

Authors:  C C Chang; A Wright; J Punnonen
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

3.  Comparison of two apheresis systems for the collection of CD14+ cells intended to be used in dendritic cell culture.

Authors:  Erwin F Strasser; Thomas G Berger; Volker Weisbach; Robert Zimmermann; Jürgen Ringwald; Beatrice Schuler-Thurner; Jürgen Zingsem; Reinhold Eckstein
Journal:  Transfusion       Date:  2003-09       Impact factor: 3.157

Review 4.  Manipulating dendritic cell biology for the active immunotherapy of cancer.

Authors:  David W O'Neill; Sylvia Adams; Nina Bhardwaj
Journal:  Blood       Date:  2004-07-01       Impact factor: 22.113

5.  A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy.

Authors:  Andrew W Lee; Tuan Truong; Kara Bickham; Jean-Francois Fonteneau; Marie Larsson; Ida Da Silva; Selin Somersan; Elaine K Thomas; Nina Bhardwaj
Journal:  Vaccine       Date:  2002-12-19       Impact factor: 3.641

6.  Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer.

Authors:  P Kaliński; P L Vieira; J H Schuitemaker; E C de Jong; M L Kapsenberg
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

Review 7.  Dendritic cell biology and cancer therapy.

Authors:  Theresa L Whiteside; Christine Odoux
Journal:  Cancer Immunol Immunother       Date:  2003-12-18       Impact factor: 6.968

Review 8.  Strategies to improve dendritic cell-based immunotherapy against cancer.

Authors:  Si Young Song; Han-Soo Kim
Journal:  Yonsei Med J       Date:  2004-06-30       Impact factor: 2.759

9.  NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses.

Authors:  Tomohiro Watanabe; Atsushi Kitani; Peter J Murray; Warren Strober
Journal:  Nat Immunol       Date:  2004-06-27       Impact factor: 25.606

10.  Functional repertoire of dendritic cells generated in granulocyte macrophage-colony stimulating factor and interferon-alpha.

Authors:  Silvia Della Bella; Stefania Nicola; Antonio Riva; Mara Biasin; Mario Clerici; Maria Luisa Villa
Journal:  J Leukoc Biol       Date:  2003-10-02       Impact factor: 4.962

View more
  7 in total

1.  Latent, Immunosuppressive Nature of Poly(lactic-co-glycolic acid) Microparticles.

Authors:  Riley P Allen; Amir Bolandparvaz; Jeffrey A Ma; Vishal A Manickam; Jamal S Lewis
Journal:  ACS Biomater Sci Eng       Date:  2018-02-03

2.  p21 Restricts HIV-1 in Monocyte-Derived Dendritic Cells through the Reduction of Deoxynucleoside Triphosphate Biosynthesis and Regulation of SAMHD1 Antiviral Activity.

Authors:  Jose Carlos Valle-Casuso; Awatef Allouch; Annie David; Gina M Lenzi; Lydia Studdard; Françoise Barré-Sinoussi; Michaela Müller-Trutwin; Baek Kim; Gianfranco Pancino; Asier Sáez-Cirión
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

Review 3.  Immune modulation by dendritic-cell-based cancer vaccines.

Authors:  Chaitanya Kumar; Sakshi Kohli; Poonamalle Parthasarathy Bapsy; Ashok Kumar Vaid; Minish Jain; Venkata Sathya Suresh Attili; Bandana Sharan
Journal:  J Biosci       Date:  2017-03       Impact factor: 1.826

4.  Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials.

Authors:  Jitka Fučíková; Daniela Rožková; Hana Ulčová; Vít Budinský; Klára Sochorová; Kateřina Pokorná; Jiřina Bartůňková; Radek Špíšek
Journal:  J Transl Med       Date:  2011-12-30       Impact factor: 5.531

5.  Direct type I IFN but not MDA5/TLR3 activation of dendritic cells is required for maturation and metabolic shift to glycolysis after poly IC stimulation.

Authors:  Austin Pantel; Angela Teixeira; Elias Haddad; Elizabeth G Wood; Ralph M Steinman; M Paula Longhi
Journal:  PLoS Biol       Date:  2014-01-07       Impact factor: 8.029

Review 6.  Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect.

Authors:  Sara Nava; Daniela Lisini; Simona Frigerio; Anna Bersano
Journal:  Int J Mol Sci       Date:  2021-11-15       Impact factor: 5.923

7.  Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy.

Authors:  Katerina Vopenkova; Klara Mollova; Ivana Buresova; Jaroslav Michalek
Journal:  J Cell Mol Med       Date:  2012-11       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.